Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,767.60
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.01
(
3.22%
)
Bitcoin
70,436.23
(
-1.13%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: biomaven0 post# 143763

Wednesday, 06/13/2012 11:24:34 AM

Wednesday, June 13, 2012 11:24:34 AM

Post# of 257257
Regeneron (REGN -8.5%) dives after privately-owned Opthotech reports positive Phase 2b results for its Fovista drug. Fovista, working in tandem with Roche's (RHHBY.PK) Lucentis, treats a form of macular degeneration, and stands to compete with Regeneron's Eylea. Lucentis. Jefferies is defending Regeneron, arguing Fovista could just as well work in tandem with Eylea.



i have no position..but watching
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now